← Eichor
Condition: Advanced Malignant Solid Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Malignant Solid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Phase 2 · 1 location(s) · Zhejiang Wenda Pharma Technology LTD. · NCT06527300HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06708663A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · 19 location(s) · Merck Sharp & Dohme LLC · NCT07247110A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Phase 2/Phase 3 · 4 location(s) · Intra-IMMUSG Pte Ltd · NCT07290088Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · TCRCure Biopharma Ltd. · NCT07487597A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1 · 19 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06859762An Exploratory Study by Fast CAR T Cells
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06327997Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
NA · 1 location(s) · Fudan University · NCT06682117Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcom
Phase 1/Phase 2 · 4 location(s) · Grupo Espanol de Investigacion en Sarcomas · NCT05146440A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07656116A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562A Study of HG381 Administered to Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · HitGen Inc. · NCT04998422A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of
Phase 1/Phase 2 · 12 location(s) · Ipsen · NCT07213817A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Phase 1/Phase 2 · 14 location(s) · Krystal Biotech, Inc. · NCT06228326Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07197827A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Aeonvital Biomedicine · NCT06257680Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
NA · 1 location(s) · UTC Therapeutics Inc. · NCT06658951IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Nanjing Immunophage Biotech Co., Ltd · NCT07508761A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1 · 21 location(s) · Nuvalent Inc. · NCT06521554A Study of NBL-028 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · NovaRock Biotherapeutics, Ltd · NCT06223256
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.